Lilly licenses CSL’s IL-6 immuno-inflammatory antibody for $100M upfront

CSL will need more than $100 million to recover from its current difficulties, but it’s a start. Eli Lilly has paid the nine-figure sum upfront for rights to the Australian company’s anti ...